Why the study?
Do 5HT2A receptor antagonists prevent peri-operative thrombosis without increasing bleeding risk in patients undergoing surgery?
Do 5HT2A receptor antagonists prevent peri-operative thrombosis without increasing bleeding risk in patients undergoing surgery?
5HT2A receptor antagonism represents a theoretically promising, neglected pharmacological approach to managing peri-operative thrombotic risk without exacerbating surgical bleeding.
Answers are grounded in this paper and cite their sources.
No increase in bleeding time supports safety evaluation; leaves open 5HT2A antagonism for peri-operative thrombosis prevention in prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mark I. M. Noble (2017) conducted a review in Stable atherothrombotic disease (n=48). ICI 170809 (Th001) vs. Placebo was evaluated on Skin bleeding time (p=0.9729).
Synapse has enriched 10 related papers. Consider them for comparative context: